2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Abstract Number: 3135

Influence of Baseline Magnetic Resonance Imaging Features on Outcomes of Operative and Non-Operative Treatment of Meniscal Tear in Patients ≥ 45
Abstract Number: 3136

Impact of Novel Smartphone Application on Pain and Mobility in Osteoarthritis Patients Treated with Hylan G-F 20
Abstract Number: 3137

Assessing System-Level Performance Measures for Early Rheumatoid Arthritis in a Large Multicenter Cross-Country Prospective 8-Year Observational Cohort Study
Abstract Number: 3138

Sustained Improvement in Follow-up of Hypertension in Rheumatology Patients: Results of an Intervention Sustainability Assessment
Abstract Number: 3139

Breaking the Cycle: Analyzing Preventable Hospital Admissions Due to Gout
Abstract Number: 3140

Assessment of American College of Rheumatology Gout Quality Measures at a University Practice Plan
Abstract Number: 3141

Development of a Glucocorticoid Toxicity Index Using Multi-Criteria Decision Analysis
Abstract Number: 3142

Improving Counseling, Documentation and Adherence to Highly Effective Birth Control in Women on Teratogenic Medications at a Rural Medical Center: A Quality Improvement Initiative
Abstract Number: 3143

The Caspase 8/RIPK3 Signaling Axis in Dendritic Cells Controls Joint Homeostasis Under Steady-State and Arthritic Conditions
Abstract Number: 3144

Role of the Gut Microbiome in Modulating Arthritis Progression in Mice
Abstract Number: 3146

Selective Deletion of a Pathogenic Subset Synovial Fibroblasts Attenuates Synovial Inflammation
Abstract Number: 3147

Remote Inflammation Triggers Autoimmune Arthritis through Th17 Distribution
Abstract Number: 3148

Peptidylarginine Deiminase 2 Is Required for Tumor Necrosis Factor Alpha Induced Citrullination and Arthritis, but Not Neutrophil Extracellular Trap Formation
Abstract Number: 3149

“Early Use of Subcutaneous MTX Monotherapy Vs. MTX Oral or Combination Therapy Significantly Delays Time to Initiating Biologics in Early RA
Abstract Number: 3150

The Initial Dose of Methotrexate per Weight Is Determinant of Disease Activity and Early DAS28 Remission in DMARD-Naive Early Rheumatoid Arthritis Patients Receiving Usual Care

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].